The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Energy Stocks Have Had a Mixed Start to 2025. Natural Gas Is Hot and Oil Is Not. Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say Black boxes analyzed ...

Breyers ice cream has been recalled due to mislabeling, Wendy's is partnering with Takis Fuego to offer a spicy chicken ...